-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
GVHD Experimental Platform of InnoModels Biotechnology: A New Era of Immune Disease Research
Author:
InnoModels Biotechnology
Release time:
2024-01-03
In the field of biomedicine, the GVHD experimental platform is an important innovation of InnoModels Biotechnology. With its unique advantages, the platform provides a new solution for immune disease research. In this article, we will introduce the various aspects of the GVHD platform to give readers an in-depth understanding of its excellent performance and prospects for wide application.
Introduction of GVHD platform of InnoModels Biotechnology
GVHD platform is a comprehensive experimental solution for immune disease research, aiming to provide one-stop service from cell model preparation, in vitro experiments to data analysis. Based on the advanced gene editing technology, the platform can realize in-depth research on the pathogenesis of GVHD through genetic modification of patient-derived T cells.
InnoModels Biotechnology GVHD Experiment Process
Patient-derived T-cell collection: obtain samples containing GVHD-related T-cells by collecting patient biopsy tissue or peripheral blood.
Gene modification: Using gene editing techniques such as CRISPR-Cas9, T cells are genetically modified to express specific antigen receptors or co-stimulatory molecules.
In vitro culture: the genetically modified T cells are co-cultured with model cells such as donor skin fibroblasts to simulate the environment of GVHD pathogenesis.
Observation and detection: GVHD-related signaling pathways were observed and detected by flow cytometry, fluorescence in situ hybridization and other techniques.
Data analysis: Combining experimental data and clinical information, in-depth analysis and interpretation of GVHD pathogenesis.

Advantages and features of GVHD experimental platform of InnoModels Biotechnology
Highly customized: Provide personalized gene modification solutions according to the specific conditions of different patients to ensure the accuracy and reliability of experimental results.
Efficient: One-stop service mode shortens the experimental cycle and improves research efficiency.
Innovative: Utilizing advanced gene editing technology, it provides new ideas and methods for GVHD research.
Reliable data: ensure the accuracy and reliability of experimental data through multi-dimensional and multi-level testing and analysis.
Application fields of GVHD experimental platform of InnoModels Biotechnology
The GVHD experimental platform is suitable for the research of various immune diseases, such as acute GVHD and chronic GVHD. The platform can provide clinicians, researchers and postgraduate students with comprehensive research support on the pathogenesis of GVHD, which helps to promote the diagnosis and treatment level of related diseases.
Conclusion
With its unique advantages and features, the GVHD experimental platform of InnoModels Biotechnology has opened up a new way for immune disease research. The platform not only improves research efficiency, but also provides reliable data support for clinicians and researchers. In the future, with the in-depth development of immune disease research, the application prospect of GVHD experimental platform will be even broader.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd